 |
|
|
| |
Towards a Single Treatment Cure for HCV: Reformulation of the Pangenotypic NS5B NNI GSK2878175 as a Long Acting Parenteral (LAP)
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Martin Leivers 1; Clint Jones 2; Pratik Saha 2; Rahul Shukla 2; Steve Englehart 3; Sujata Patel 2; Jayadevan Jayadevan Thekele 2; Kelong Han 3; Joseph Kim 4; Dickens Theodore 1; Zhi Hong 1
1GlaxoSmithKline, Research Triangle Park, North Carolina, UNITED STATES;
2GlaxoSmithKline, Collegeville, Pennsylvania, UNITED STATES; 3GlaxoSmithKline, King of Prussia, Pennsylvania, UNITED STATES; 4 PAREXEL International, Durham, North Carolina, UNITED STATES
RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up....
http://www.natap.org/2016/HCV/021916_04.htm
|
| |
|
|
|
|
|
